 Apellis Pharmaceuticals Inc NASDAQ: APLS shares are trading higher Tuesday after the company announced the U.S. Food and Drug Administration accepted and granted priority review designation for the new drug application for Pegcetacoplan. Pegcetacoplan is an investigational,. 